BIO, PhRMA, GPhA Urge FDA To Stand Firm On Compounding Enforcement

Key brand and generic drug industry associations are throwing their support behind FDA's drug compounding enforcement activities, writing to the agency that it shouldn't be swayed by drug compounders' press to allow some compounding without patient-specific prescriptions. The letter comes as drug compounding stakeholders craft a legislative strategy to counter FDA's stance against office-use compounding. The Biotechnology Industry Organization, Generic Pharmaceutical Association, Pharmaceutical Research and Manufacturers of America and the Pew Charitable Trusts are among the stakeholders signing the letter...